-
Wuhan Tests All Residents as Delta Variant Rages Where Pandemic Began
drugs
August 05, 2021
All 11 million residents of the city of Wuhan will be tested for COVID-19 after three locally transmitted cases were reported in the city on Monday, Chinese officials said Tuesday.
-
REGEN-COV Authorized for Postexposure Prophylaxis in High-Risk Individuals
August 05, 2021
The monoclonal antibody therapy REGEN-COV was authorized for emergency use as a postexposure prophylaxis for COVID-19 in those at high risk for severe disease, the U.S. Food and Drug Administration announced Friday.
-
WHO Slams COVID-19 Booster Shots in Wealthy Nations
drugs
August 05, 2021
Wealthy nations should not be giving COVID-19 vaccine booster shots to their citizens while poor nations struggle to get first doses of vaccines, the World Health Organization said Wednesday.
-
Disposable Respiratory Masks Market 2021-2025 | Post COVID-19 Impact Analysis | Technavio
prnewswire
August 05, 2021
The disposable respiratory masks market is poised to show a decremental growth of USD 6.70 billion during 2021-2025, progressing at a CAGR of about (19)% during the forecast period.
-
Digital Publishing Market to grow by USD 65.31 billion - COVID-19 Impact & Recovery Analysis|Key Drivers and Market Forecasts|17000+ Technavio Reports
prnewswire
August 05, 2021
According to Technavio, incremental growth of USD 65.31 billion is expected in the digital publishing market during 2021-2025.
-
Adamis Announces Agreement to Sell Portion of US Compounding Business
firstwordpharma
August 05, 2021
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it has entered into a definitive agreement to sell a significant portion of the assets of its subsidiary, US Compounding Inc. (USC), related to USC's human compounding pharmaceutical
-
New England Journal of Medicine Publishes Positive Phase 3 Trial Results for REGEN-COV (casirivimab and imdevimab) to Prevent SARS-CoV-2 Infection
firstwordpharma
August 05, 2021
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the New England Journal of Medicine(NEJM) published positive detailed results from a Phase 3 trial that assessed the ability of REGEN-COV™ (casirivimab and imdevimab) to prevent COVID-19.
-
Full-dose blood thinners reduce the need for organ support in moderately ill COVID-19 patients, but not in critically ill patients
firstwordpharma
August 05, 2021
A large clinical trial conducted worldwide shows that treating moderately ill hospitalized COVID-19 patients with a full-dose blood thinner reduced their need for organ support, such as mechanical ventilation, and improved their chances .
-
Miller School Research Reveals that Flu Shot Protects Against Severe Effects of COVID-19
firstwordpharma
August 05, 2021
In a newly published study, physician-scientists at the University of Miami Miller School of Medicine have shown that the flu vaccine may provide vital protection against COVID-19.
-
Bio-Techne's RNAscope™ Technology Aids in the Retrospective Tissue Diagnosis of COVID-19 in cases with no previous testing for SARS-CoV-2
prnewswire
August 05, 2021
Bio-Techne Corporation (NASDAQ: TECH) today announced that scientists at the U.S. Centers for Disease Control and Prevention (CDC) recently highlighted the importance of fixed tissue analysis for retrospective diagnosis of SARS-CoV-2 infection
ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
The monoclonal antibody therapy REGEN-COV was authorized for emergency use as a postexposure prophylaxis for COVID-19 in those at high risk for severe disease, the U.S. Food and Drug Administration announced Friday.
Pharma Sources Insight July 2025
